Developing Prioritization Criteria to Identify Target Drugs for CalRx, the California Generic Drugs Initiative

May 1, 2023, 00:00 AM
10.1016/j.jval.2022.11.004
https://www.valueinhealthjournal.com/article/S1098-3015(22)04734-9/fulltext
Section Title : BRIEF REPORT
Section Order : 634
First Page : 634

Objectives

This study aimed to establish criteria to identify priority drugs for CalRx, a California-sponsored initiative to support the manufacture and distribution of affordable generic drugs.

Methods

A web-based ranking exercise was implemented with key stakeholders in August 2020, using pricing, spending, and public health criteria identified through a review of academic literature and public health agency reports. A total of 39 of 40 invited stakeholders in 4 different categories—patient advocates, healthcare providers, health insurers, and health policy and economic experts—participated in this study (98% response rate).

Results

Drugs that treat large populations, drugs that represent high cost to payors, and drugs that represent high cost to consumers were ranked a priority, receiving > 10% of ranking weights. Drugs that treat conditions with high morbidity or mortality, drugs without therapeutic alternatives, and drugs treating vulnerable populations represented criteria of further interest (9%-10% of weights). Shortage risk and curative effect (8%-9% of the weights), high price increases, communicable disease treatments, and high unit prices ( 8% of the weights) represented the bottom of the priority distribution.

Conclusions

This study suggests that drugs that treat large populations, drugs that represent large costs to payors, and drugs that represent large costs to consumers should be the priority for California’s CalRx generic drug initiative. A prioritizing algorithm will assist California in determining top drugs to target from a public health and spending perspective as it plans the rollout of the CalRx initiative and negotiates with drug manufacturers.

https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)04734-9&doi=10.1016/j.jval.2022.11.004
HEOR Topics :
  • Generics
  • Health Policy & Regulatory
  • Public Spending & National Health Expenditures
  • Specialized Treatment Areas
  • Study Approaches
  • Surveys & Expert Panels
Tags :
  • drug access and affordability
  • drug manufacturing and distribution
  • generic drug markets
  • prescription drugs
  • prioritization framework
  • state health policy
Regions :
  • North America